The American Diabetes Association’s (ADA) 80th Scientific Sessions starts today (12 June) with over 800 presentations being delivered across more than 200 virtual sessions.
The program will also feature a virtual Poster Hall, virtual Exhibit Hall and virtual receptions.
Originally scheduled for Chicago before COVID-19 changed everyone’s plans, the ADA Scientific Sessions are still promising the same quality of science and exchange.
“This is not a watered-down version of the Scientific Sessions,” Dr Jose Florez said.
“With very few exceptions, it’s the full meeting that was envisioned before COVID-19 struck, but now in a format that is accessible to all and on their own time. It’s the same amount of science delivered by the same speakers who were selected before COVID, but now attendees can access it from the comfort of their homes without incurring any risks.”
Dr Florez, chair of the Scientific Sessions Planning Committee, said presentations have been pre-recorded and will be released at their originally scheduled time.
Registered attendees will receive unlimited access to virtual content for 90 days after the virtual event.
New data will be presented from pivotal studies including:
- eValuation of ERTugliflozin EffIcacy and Safety CardioVascular Outcomes Trial (VERTIS-CV)
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF)
- Diabetes Prevention Program Outcomes Study (DPPOS)
- The Environmental Determinants of Diabetes in the Young (TEDDY) study.
- The Search for Diabetes in Youth study.
The limbic will be covering some of the highlights of the meeting in future newsletters and on Twitter @thelimbicendo #ADA2020 #ADAGoesVirtual